Frontiers in Molecular Biosciences (Mar 2023)

The cyclic peptide G4CP2 enables the modulation of galactose metabolism in yeast by interfering with GAL4 transcriptional activity

  • Stefano Rosa,
  • Andrea Tagliani,
  • Chiara Bertaso,
  • Luca Tadini,
  • Cristina Visentin,
  • Louise Jane Gourlay,
  • Sabrina Pricl,
  • Sabrina Pricl,
  • Lucia Feni,
  • Sara Pellegrino,
  • Paolo Pesaresi,
  • Simona Masiero

DOI
https://doi.org/10.3389/fmolb.2023.1017757
Journal volume & issue
Vol. 10

Abstract

Read online

Genetically-encoded combinatorial peptide libraries are convenient tools to identify peptides to be used as therapeutics, antimicrobials and functional synthetic biology modules. Here, we report the identification and characterization of a cyclic peptide, G4CP2, that interferes with the GAL4 protein, a transcription factor responsible for the activation of galactose catabolism in yeast and widely exploited in molecular biology. G4CP2 was identified by screening CYCLIC, a Yeast Two-Hybrid-based combinatorial library of cyclic peptides developed in our laboratory. G4CP2 interferes with GAL4-mediated activation of galactose metabolic enzymes both when expressed intracellularly, as a recombinant peptide, and when provided exogenously, as a chemically-synthesized cyclic peptide. Our results support the application of G4CP2 in microbial biotechnology and, additionally, demonstrate that CYCLIC can be used as a tool for the rapid identification of peptides, virtually without any limitations with respect to the target protein. The possible biotechnological applications of cyclic peptides are also discussed.

Keywords